Village Farms International: Global Cannabis Powerhouse Gains Institutional Backing as International Sales Surge

A Global Cannabis Platform in Overdrive

Village Farms International reported a second quarter that underscores its transformation from a diversified agricultural producer into a pure-play global cannabis operator. Consolidated net sales rose 7% year-over-year to $64 million, driven by a record quarter for international medical exports, which surged 74% year-over-year and 43% sequentially. The company delivered its fifth consecutive quarter of positive net income and adjusted EBITDA of $15.4 million, with cannabis gross margins expanding 900 basis points to 51%. As CEO Mike DeGiglio put it, “Our second quarter results continue to demonstrate the strength of our expanding global cannabis platform.” — Mike DeGiglio, Chief Executive Officer · 2026-08-10

The engine behind this growth is the EU GMP certified production complex in Delta, British Columbia. Management has consistently argued that the world's largest EU GMP facility gives them a durable cost and regulatory advantage. In the Q&A, COO Ann Gillin Lefever asserted, “We think we are the largest Canadian exporter by volume.” — Ann Gillin Lefever, Chief Operating Officer · 2026-08-10 The company now holds four of the top ten strains in the German market and believes it has the widest pharmacy distribution among cultivators. This is not a new story—on the May call, management had already highlighted that “for our specifically EU GMP certified product, we have not seen really any margin compression.” — Mike DeGiglio, Chief Executive Officer · 2026-05-11 But the magnitude of international growth this quarter, plus the ongoing capacity expansion, suggests the moat is deepening.

Capital Infusion and Institutional Backing

Perhaps the most consequential development in Q2 was the completion of a $15 million equity placement with two U.S. institutional investors. This is a strategic milestone for a company that has been largely retail-owned and now signals growing institutional confidence in the global cannabis thesis. CFO Steve Ruffini noted the company ended the quarter with $73 million in cash and a net cash position of $33 million, after paying a full year-and-a-half of Canadian income taxes ($17 million) and $31 million in excise taxes. “We believe we are the first and only major Canadian public cannabis LP in the position of paying corporate income taxes,” — Steve Ruffini, Chief Financial Officer · 2026-08-10 Ruffini said, highlighting the sustainability of the platform.

The transfer pricing policy update also drew attention. Management explained that with the produce business now privatized, a larger share of corporate expenses is directly allocated to cannabis, which temporarily inflated SG&A as a percentage of sales. This is a one-time accounting shift, not a deterioration in operating efficiency—the underlying adjusted EBITDA margin actually expanded meaningfully when excluding last year's vendor settlement.

Produce Residuals and Tariff Tailwinds

While cannabis is the future, the legacy produce business continues to contribute. The U.S. suspension agreement with Mexico was terminated, imposing a 17% tariff on Mexican tomatoes, which has boosted domestic pricing. Gross margin in the produce segment jumped to 26% from 11% a year ago. This is a nice counter-cyclical hedge while the company scales its international cannabis footprint.

Forward-Looking Catalysts

The company's Delta 2 expansion is on track: the first half is already in production, and the second half conversion begins September 1. Management expects an incremental 40 metric tons of annual production by 2027, with the Netherlands' Groningen facility ramping to full capacity by Q1 2027. As Mike DeGiglio has said before, "It's just not a matter of getting a DEA export license... but maintaining it is even more difficult," underscoring that the high barriers to entry protect their position. In November, he had already been confident, “I wouldn't be surprised if we're number one in whatever that market share number is.” — Michael DeGiglio, CEO · 2025-11-10

The balance sheet is the final pillar. Effective Net Cash turned positive to $15 million as of the latest filing, and management expects to grow cash further in H2. With CapEx largely behind them, free cash flow should inflect upward—a key re-rating catalyst for a company trading at ~1.4x revenue.

We're leaving around $50 million of revenue on the table right now.